Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Exosomes in Treating Chronic Cough After COVID-19
Long COVID-19 Syndrome
About this trial
This is an interventional treatment trial for Long COVID-19 Syndrome focused on measuring COVID-19, Chronic Cough
Eligibility Criteria
Inclusion Criteria: Trial participants voluntarily participate in this study and sign an informed consent form. At the time of signing the informed consent form, the age of the subject should be ≥18 or ≤80 years old, with no gender restrictions. The subject has been diagnosed with COVID-19 (confirmed by positive nucleic acid or antigen test) and has symptoms that have lasted for more than 4 weeks. Negative nucleic acid or antigen test at the time of screening. The subject has had continuous or intermittent coughing, or loss of taste/smell for ≥4 weeks, which did not occur before the onset of COVID-19 infection. No prior treatment with umbilical cord mesenchymal stem cell-derived extracellular vesicles. The patient fully understands the purpose and requirements of this clinical study and is willing to complete all trial procedures according to the study requirements. Exclusion Criteria: Age ≤18 or ≥80 years old. Acute COVID-19 patients. Suspected or confirmed to have severe, active bacterial, fungal, or other infections that may pose a risk when intervention measures are taken, as determined by the researcher. Patients with a history of diagnosed bronchial asthma, cough variant asthma, or chronic cough; patients with other pulmonary diseases such as chronic obstructive pulmonary disease, bronchiectasis, tuberculosis, lung cancer, etc. Any of the following during the screening period: 1) ALT or AST > 3 times the upper limit of normal; 2) eGFR <60 mL/min. Patients with a history of severe allergies. Patients with uncontrolled severe cardiovascular, cerebrovascular, liver, kidney, endocrine, blood system diseases, and mental illness. Patients with active immunosuppression, immunodeficiency, and use of immunosuppressive drugs. Pregnant and lactating women. Other factors that the researcher deems unsuitable for participation in the study based on clinical considerations.
Sites / Locations
- Huazhong University of Science and Technology Union Shenzhen HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Exosomes treatment group
Non-treatment group
Treated with umbilical cord mesenchymal stem cell-derived extracellular vesicles (EVs) preparation (Specification: 5ml, EV concentration of 1*10^9 particles /ml)
No treatment